Vancouver, British Columbia (FSCwire) - BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX, FSE:20B) is pleased to announce that BioMark has been granted an Investigational Testing Authorization (ITA”) by Health Canada’s Therapeutic Products Directorate (“TPD”) adopting the Company’s protocols and reference standards for reference laboratories across Canada. The authorization also will allow BioMark to sell up to one hundred and eighty (180) of these devices as part of the ITA for investigational purposes.
The ITA recognizes the proprietary protocol the Company has developed and internationally patented for urinary excretion of Acetylamantadine by cancer patients. This protocol involves the use of BioMark’s Acetylamantadine Assay Standard for Liquid Chromatography – tandem Mass Spectrometry (LC-MS/MS). This assay was developed by BioMark in order to establish a clinical diagnostic reference standard as part of the protocol when evaluating urinary excretion of acetylamantadine as a predication cancer presence.
President and CEO of BioMark, Rashid Ahmed comments: “This is a necessary achievement for BioMark since we utilized industry gold standard using LC-MS/MS. The authorization provides BioMark the ability to conduct tests for validating the use of our internal system for labs and sets the stage for licensing later.”
The regulatory submission and documentation was guided by the regulatory team at St. Boniface Hospital Research Centre.
About BioMark Diagnostics Inc.
BioMark is developing proprietary, non-invasive, and accurate cancer diagnostic solutions which can help detect, monitor and assess treatment for cancer early and cost effectively. The technology can also be used for measuring response to treatment and potentially for serial monitoring for cancer survivors.
Further information about BioMark is available under its profile on the SEDAR website www.sedar.com and on the CSE website www.thecse.ca.
For further information on BioMark, please Contact:
Rashid Ahmed Bux
President & CEO
BioMark Diagnostics Inc.
Tel. 604-282-6567
Email: info@biomarkdiagnostics.com
Forward-Looking Information:
This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of BioMark. Forward-looking information is based on certain key expectations and assumptions made by the management of BioMark. Although BioMark believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because BioMark can give no assurance that they will prove to be correct. Forward-looking statements contained in this press release are made as of the date of this press release. BioMark disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.
This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in the United States. The securities described herein have not been and will not be registered under the United States Securities Act of 1933, as amended, or any applicable securities laws or any state of the United States and may not be offered or sold in the United States or to the account or benefit of a person in the United States absent an exemption from the registration requirements.
The CSE has not reviewed, approved or disapproved the content of this press release.
To view this press release as a PDF file, click onto the following link:
public://news_release_pdf/BioMarkDec82014.pdfSource: BioMark Diagnostics Inc (CSE:BUX) http://www.biomarkdiagnostics.com/
Maximum News Dissemination by FSCwire. http://www.fscwire.com
Copyright © 2014 Filing Services Canada Inc.